Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1966 1
1975 1
1982 1
1983 4
1984 4
1985 3
1986 2
1990 2
1991 1
1992 2
1993 1
1994 1
1995 1
1997 1
1998 2
1999 1
2000 3
2001 11
2002 9
2003 6
2004 8
2005 13
2006 7
2007 8
2008 14
2009 18
2010 13
2011 16
2012 16
2013 20
2014 14
2015 20
2016 15
2017 25
2018 32
2019 21
2020 26
2021 36
2022 34
2023 32
2024 37
2025 43
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

476 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean fetter m[au] (191 results)?
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study.
Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G; GRAVITI Study Group. Hart A, et al. Among authors: vetter ml. Gastroenterology. 2025 Aug;169(2):308-325. doi: 10.1053/j.gastro.2025.02.033. Epub 2025 Mar 18. Gastroenterology. 2025. PMID: 40113101 Free article. Clinical Trial.
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panés J; VEGA Study Group. Feagan BG, et al. Among authors: vetter m. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1. Lancet Gastroenterol Hepatol. 2023. PMID: 36738762 Clinical Trial.
Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy.
Correia AL, Guimaraes JC, Auf der Maur P, De Silva D, Trefny MP, Okamoto R, Bruno S, Schmidt A, Mertz K, Volkmann K, Terracciano L, Zippelius A, Vetter M, Kurzeder C, Weber WP, Bentires-Alj M. Correia AL, et al. Among authors: vetter m. Nature. 2021 Jun;594(7864):566-571. doi: 10.1038/s41586-021-03614-z. Epub 2021 Jun 2. Nature. 2021. PMID: 34079127
PIK3CA-mutations in breast cancer.
Reinhardt K, Stückrath K, Hartung C, Kaufhold S, Uleer C, Hanf V, Lantzsch T, Peschel S, John J, Pöhler M, Bauer M, Bürrig FK, Weigert E, Buchmann J, Kantelhardt EJ, Thomssen C, Vetter M. Reinhardt K, et al. Among authors: vetter m. Breast Cancer Res Treat. 2022 Dec;196(3):483-493. doi: 10.1007/s10549-022-06637-w. Epub 2022 Oct 24. Breast Cancer Res Treat. 2022. PMID: 36279023 Free PMC article.
Neutrophils escort circulating tumour cells to enable cell cycle progression.
Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, Scheidmann MC, Donato C, Scherrer R, Singer J, Beisel C, Kurzeder C, Heinzelmann-Schwarz V, Rochlitz C, Weber WP, Beerenwinkel N, Aceto N. Szczerba BM, et al. Among authors: vetter m. Nature. 2019 Feb;566(7745):553-557. doi: 10.1038/s41586-019-0915-y. Epub 2019 Feb 6. Nature. 2019. PMID: 30728496
The metastatic spread of breast cancer accelerates during sleep.
Diamantopoulou Z, Castro-Giner F, Schwab FD, Foerster C, Saini M, Budinjas S, Strittmatter K, Krol I, Seifert B, Heinzelmann-Schwarz V, Kurzeder C, Rochlitz C, Vetter M, Weber WP, Aceto N. Diamantopoulou Z, et al. Among authors: vetter m. Nature. 2022 Jul;607(7917):156-162. doi: 10.1038/s41586-022-04875-y. Epub 2022 Jun 22. Nature. 2022. PMID: 35732738
Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells.
Donato C, Kunz L, Castro-Giner F, Paasinen-Sohns A, Strittmatter K, Szczerba BM, Scherrer R, Di Maggio N, Heusermann W, Biehlmaier O, Beisel C, Vetter M, Rochlitz C, Weber WP, Banfi A, Schroeder T, Aceto N. Donato C, et al. Among authors: vetter m. Cell Rep. 2020 Sep 8;32(10):108105. doi: 10.1016/j.celrep.2020.108105. Cell Rep. 2020. PMID: 32905777 Free PMC article.
Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding.
Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, Scherrer R, Krol I, Scheidmann MC, Beisel C, Stirnimann CU, Kurzeder C, Heinzelmann-Schwarz V, Rochlitz C, Weber WP, Aceto N. Gkountela S, et al. Among authors: vetter m. Cell. 2019 Jan 10;176(1-2):98-112.e14. doi: 10.1016/j.cell.2018.11.046. Cell. 2019. PMID: 30633912 Free PMC article.
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.
Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Panés J, Danese S, Hisamatsu T, Terry NA, Salese L, Van Rampelbergh R, Sahoo A, Vetter ML, Yee J, Han C, Frustaci ME, Wan KYY, Yang Z, Johanns J, Andrews JM, D'Haens GR, Sands BE; GALAXI 2 & 3 Study Group. Panaccione R, et al. Among authors: vetter ml. Lancet. 2025 Jul 26;406(10501):358-375. doi: 10.1016/S0140-6736(25)00681-6. Epub 2025 Jul 17. Lancet. 2025. PMID: 40684778 Clinical Trial.
Top Ten Tips Palliative Care Clinicians Should Know About Total Pain.
Hamza Habib M, Zheng J, Kozlov E, Peng-Keller S, Ciurea A, Schildmann J, Schildmann E, Gaertner J, Hogan J, Vetter M, Tolchin DW, Coyne P, Rosa WE, Chwistek M, Jones CA, Schlögl M. Hamza Habib M, et al. Among authors: vetter m. J Palliat Med. 2026 Feb;29(2):237-244. doi: 10.1089/jpm.2025.0159. Epub 2025 May 7. J Palliat Med. 2026. PMID: 40329910
476 results